Market capitalization | $187.46m |
Enterprise Value | $182.84m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 30.92 |
Sales growth (TTM) Sales growth | -100.00% |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-36.50m |
Free cash flow (TTM) Free cash flow | $-32.19m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
1 Analyst has issued a forecast Candel Therapeutics Inc:
1 Analyst has issued a forecast Candel Therapeutics Inc:
Mar '24 |
+/-
%
|
||
Turnover | - - |
-
|
|
Gross income | -1.16 -1.16 |
20%
20%
|
|
EBITDA | -35 -35 |
3%
3%
|
EBIT (operating result) EBIT | -36 -36 |
3%
3%
|
Net profit | -37 -37 |
40%
40%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
Head office | United States |
CEO | Paul-Peter Tak |
Employees | 42 |
Founded | 2002 |
Website | www.candeltx.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.